Abstract: The invention relates to beneficial topical pharmaceutical compositions comprising the diclofenac sodium salt in unusually low amounts. The compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.

Abstract: The invention relates to methods for treating burns or inflammation utilizing beneficial pharmaceutical compositions comprising diclofenac sodium salt in unusually low amounts. The compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.

Abstract: The present invention provides a chewable composition containing granules of water-soluble dietary fiber. The chewable composition has highly agreeable organolpetic properties and is consumable without the need of an ingestion aid.

Abstract: The present invention is directed to patient-controlled, flexible-dosing methods of treatment utilizing transdermal nicotine patch devices, optionally with other nicotine delivery systems, to abate the use of tobacco in humans.

Abstract: A controlled release lozenge having pleasant organoleptic properties, said lozenge consisting essentially of (a) a soluble filler which is selected from the group consisting of maltitol, xylitol, sorbitol, mannitol, lactose, dextrose, saccharose, fructose, and mixtures thereof; (b) an insoluble film forming agent which is capable of forming an insoluble matrix, said insoluble film forming agent is selected from the group consisting of a polyacrylate, ethyl cellulose, polyvinylchloride, cellulose acetate, cellulose acetate phthalate, and shellac; (c) a swellable polymer which is selected from the group consisting of xanthan gum, guar gum, alginic acid or a salt thereof, pectin, polyvinyl alcohol, polysaccharide, and cellulose derivatives; and (d) at least one active substance.

Abstract: The present invention relates to a solid pharmaceutical dosage form for oral administration, consisting essentially of(a) at least one active substance,(b) at least one filler,(c) at least one binding agent, and(d) optionally usual auxiliaries,which dosage form, however, does not contain agar;which dosage form is manufactured without applying any compression force to the mixture of the components (a), (b), (c) and (d); andwhich dosage form disintegrates when taken into the mouth within 15 seconds.

Abstract: The invention relates to processes for preparing substituted aromatic amino compounds which contain at least one unsaturated --CN bond or carbonyl group on the aromatic radical or in a side chain, by catalytic hydrogenation of appropriate substituted aromatic nitro compounds in the presence of a modified noble metal catalyst of platinum which is modified with a metal selected from lead, mercury, bismuth, germanium, cadmium, arsenic, antimony, silver and gold.